22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
One effect of the COVID-19 pandemic has been to accelerate the implementation of new or stricter con...
Read More >
Publicly traded companies need to know whether a director qualifies as "independent" for a variety o...
Read More >
The Nevada Labor Commissioner issued two advisory opinions concerning Senate Bill (SB) 312, which, e...
Read More >
Since April 30, 2018, when the landmark California Supreme Court decision in Dynamex Operations West...
Read More >
As part of the Tax Cuts and Jobs Act of 2017, the cost of providing certain transportation fringe be...
Read More >
Two years after the enactment of the Tax Cuts and Jobs Act (TCJA), the most significant tax reform e...
Read More >